Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 5, 1998, Pages 798-806

  Rizzoni, Damiano ^a   Porteri, Enzo ^a   Bettoni, Giorgio ^a   Piccoli, Alfonso ^a   Castellano, Maurizio ^a   Muiesan, Maria Lorenza ^a   Pasini, Giancarlo ^a   Guelfi, Daniele ^a   Rosei, Enrico Agabiti ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Scienze Mediche   (Italy)

Author keywords

ACE inhibitors; Acetylcholine; Angiotensin II; Candesartan cilexetil; EDRF; Enalapril; Endothelium; Hypertrophy; Vascular hypertrophy; Vascular resistance

Indexed keywords

CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG EFFECT; HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RESISTANCE;

ACETYLCHOLINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; ENDOTHELIUM, VASCULAR; HEART; HYPERTENSION; MESENTERIC ARTERIES; NITROPRUSSIDE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TETRAZOLES;

EID: 0031734369     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199811000-00017     Document Type: Article

References (47)

1. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23:83-91.
2. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25(Pt 1):474-81.
3. Rizzoni D, Muiesan ML, Porten E, et al. Effect of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997;15:197-204.
4. Freslon JL, Giudicelli JF. Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br J Pharmacol 1983;80:533-43.
5. Rizzoni D, Castellano M, Porteri E, et al. Effects of low and high doses of fosinopril on the structure and function of resistance arteries. Hypertension 1995;26:118-23.
6. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens 1989;7:83-90.
7. Harrap SB, Van der Merwe WM, Griffin SA, MacPherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long term. Hypertension 1990;16:603-14.
8. Adams MA, Bobik A, Korner PI. Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats. Hypertension 1990;16:252-60.
9. Rizzoni D, Castellano M, Porteri E, et al. Prolonged effects of short-term fosinopril on blood pressure and vascular morphology and function in rats. Am J Hypertens 1997;10:1034-43.
10. Gibbons GH. Angiotensin-converting enzyme inhibition and vascular structure in hypertension. J Cardiovasc Pharmacol 1991;18(suppl 7):S19-24.
11. Timmermans PBMWM, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994;(suppl D):79-87.
12. Unger T, Chung O, Csikos T, et al. Angiotensin receptors. J Hypertens 1996;14(suppl 5):S95-103.
13. Kaneko K, Susic D, Nunez E, Frohlich ED. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens 1996;14:645-53.
14. Gohlke P, Linz W, Schölkens A, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996;28:397-402.
15. 1 angiotensin-receptor blockade on structure and function of small resistance arteries in SHR. J Cardiovasc Pharmacol 1997;30:75-83.
16. Ledingham JM, Laverty R. Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonists. Clin Exp Pharmacol Physiol 1996;23:576-8.
17. Morton JJ, Beattie EC, MacPherson F. Angiotensin II receptor antagonists losartan has persistent effect on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res 1992;29:264-9.
18. Shaw LM, George PR, Oldham AA, Heagerty AM. A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on structural changes associated with hypertension in rat small arteries. J Hypertens 1995;13: 1135-43.
19. deBlois D, Tea BS, Dam TV, Tremblay J, Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997;29(Pt 2):340-9.
20. Lüscher TF, Tschudi MR, Dohi Y. Resistance arteries in hypertension: role of the endothelium. In: Mulvany MJ, Aalkjaer C, Heagerty AM, Nyborg NCB, Strandgaard S, eds. Resistance arteries: structure and function. Amsterdam: Elsevier Science Publishers B.V., 1991:312-5.
21. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti-Rosei E. Vascular structural and functional alterations before and after the development of hypertension in SHR. Am J Hypertens 1994;7:193-200.
22. Dohi Y, Criscione L, Pfeiffer K, Lüscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994;24:372-9.
23. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Anti-hypertensive therapy augments endothelium-dependent relaxation in coronary arteries of spontaneously hypertensive rats. Circulation 1994;89:2212-8.
24. Morimoto S, OgiharaT. TCV-116, a new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev 1994;12(2):153-64.
25. Mizuno K, Niimura S, Tani M, et al. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci 1992;51:183-7.
26. Garcha RS, Schachter M, Sever PS, Hughes AD. Action of candesartan in human subcutaneous resistance arteries. Abstracts of the 6th European Meeting on Hypertension, Milan, Italy 1995:66.
27. Mulvany MJ, Halpern W. Contractile properties of small resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977;41:19-26.
28. Mulvany MJ, Hansen PK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res 1978;43(6): 854-64.
29. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985;6:161-4.
30. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti Rosei E. Delayed development of hypertension after short-term nitrendipine treatment. Hypertension 1994;24:131-9.
31. Rodrigo E, Maeso R, Muñoz-Garcìa R, et al. Endothelial dysfunction in spontaneously hypertensive rats: consequence of chronic treatment with losartan or captopril. J Hypertens 1997;15:613-8.
32. Kerth PA, Vanhoutte PM. Effects of perindoprilat on endothelium-dependent relaxation and contractions in isolated blood vessels. Am J Hypertens 1991;4:226S-34S.
33. Ciozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension 1991;18(2):132-41.
34. Vanhoutte PM, Aush-Schwelk W, Biondi ML, Lorenz RR, Schini VB, Vidal MJ. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol 1989;28:95S-104S.
35. Mombouli JV, Vanhoutte PM. Kinins and endothelium-dependent relaxations to converting enzyme inhibitors in perfused canine arteries. J Cardiovasc Pharmacol 1991;18:926-7.
36. Küng CF, Lüscher TF. Different mechanisms of endothelial dysfunction with ageing and hypertension in rat aorta. Hypertension 1995;25:194-200.
37. Castellano M, Rizzoni D, Beschi M, et al. Chronic ACE-inhibitor treatment and adrenergic mechanisms in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995;26:381-7.
38. Black MJ, Bertram JF, Campbell JH, Campbell GR. Angiotensin II induces cardiovascular hypertrophy in perindopril-treated rats. J Hypertens 1995;13:683-92.
39. Griffin SA, Brown WCB, MacPherson F, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626-35.
40. Lundie MJ, Friberg P, Line RL, Adams MA. Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. J Hypertens 1997;15:339-48.
41. Vacher E, Fornes P, Richer C, Bruneval P, Nisato D, Giudicelli JF. Early and late haemodynamic and morphological effects of angiotensin II subtype I receptor blockade during genetic hypertension development. J Hypertens 1995;13:675-82.
42. Kabour A, Henegar JR, Devinemi VR, Janicki JS. Prevention of angiotensin II-induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res 1995;29:543-8.
43. Fornes P, Richer C, Vacher E, Bruneval P, Giudicelli JF. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persists durably after treatment withdrawal. J Cardiovasc Pharmacol 1993;22:305-13.
44. Vacher E, Richer C, Giudicelli JF. Effect of losartan on cerebral arteries in stroke prone spontaneously hypertensive rats. J Hypertens 1996;14:1341-8.
45. Mulvany MJ. Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. J Hum Hypertens 1995;9:479-85.
46. Lew MJ. Wall stress and wall to lumen ratios differ between pressurised and myograph-mounted arteries. Amsterdam: Elsevier Science Publishers B.V., 1991:353-6.
47. Buus NH, VanBavel E, Mulvany MJ. Differences in sensitivity of rat mesenteric small arteries to agonists when studied as ring preparations or as cannulated preparations. Br J Pharmacol 1994;112:579-87.